U.S. markets closed

Tactile Systems Technology, Inc. (TCMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
55.54+0.28 (+0.51%)
At close: 4:00PM EDT

55.54 0.00 (0.00%)
After hours: 5:33PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close55.26
Open55.76
Bid55.38 x 800
Ask55.45 x 1100
Day's Range55.18 - 57.01
52 Week Range30.31 - 64.53
Volume93,024
Avg. Volume160,154
Market Cap1.09B
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateApr 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tactile Medical to Release First Quarter of Fiscal Year 2021 Financial Results on May 3, 2021
    GlobeNewswire

    Tactile Medical to Release First Quarter of Fiscal Year 2021 Financial Results on May 3, 2021

    MINNEAPOLIS, April 08, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Monday, May 3. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 3 to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13718669. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13718669. The webcast will be archived at investors.tactilemedical.com. About Tactile Medical Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions. CONTACT: Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners investorrelations@tactilemedical.com

  • Tactile Systems Technology (TCMD) Moves 7.1% Higher: Will This Strength Last?
    Zacks

    Tactile Systems Technology (TCMD) Moves 7.1% Higher: Will This Strength Last?

    Tactile Systems Technology (TCMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • Tactile Medical Appoints Kristie Burns as Senior Vice President of Marketing & Clinical Affairs
    GlobeNewswire

    Tactile Medical Appoints Kristie Burns as Senior Vice President of Marketing & Clinical Affairs

    MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, announced the appointment of Kristie Burns to the position of Senior Vice President of Marketing & Clinical Affairs, effective March 22, 2021. Ms. Burns will succeed Darren Wennen, who was promoted from Vice President of Marketing & Clinical Affairs to Senior Vice President of Commercial Operations. “With over 25 years in the healthcare industry, Kristie brings a wealth of commercial leadership experience in the treatment of chronic conditions with connected at-home solutions,” said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. “Having developed markets with underdiagnosed/undertreated conditions at both ResMed and Cala Health, I expect her to help strengthen our market penetration efforts which will lead to more patients getting the treatment they deserve. I am very pleased to welcome Kristie to Tactile Medical and look forward to her contributions as a member of our executive leadership team.” Prior to joining Tactile Medical, Ms. Burns was the Chief Marketing Officer at Cala Health, Inc., a privately-held bioelectronic medicine company developing wearable neuromodulation therapies for chronic disease. At Cala Health, she organized the company’s commercial functions and managed the U.S. commercial introduction of its lead product. Ms. Burns previously worked for 13 years at ResMed Inc. (NYSE: RMD) a global leader in digital health and cloud-connected medical devices focused on sleep apnea and other chronic diseases. She joined ResMed as a Market Development Manager in 2003 and subsequently held multiple positions of increasing responsibility culminating as Vice President of Solutions Marketing for ResMed Americas. She began her career with a privately-held cardiology consulting practice that was subsequently acquired by GE Medical Systems. “I’m very pleased to join Dan and the team to fuel healthy growth and the expansion of Tactile Medical,” said Ms. Burns. “Moreover, I’m excited to continue advancing the impact of at-home therapies for people living with chronic conditions.” About Tactile Medical Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions. Legal Notice Regarding Forward-Looking Statements: This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations; the course of the COVID-19 pandemic and its impact on general economic, business and market conditions; the Company’s inability to execute on its plans to respond to the COVID-19 pandemic; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners investorrelations@tactilemedical.com